Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
주식 순위 #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
주가
$206.50
시가총액
$365.13B
변동 (1일)
-0.31%
변동 (1년)
2.58%
국가
US
거래 AbbVie Inc. (ABBV)

카테고리

AbbVie Inc. (ABBV)의 영업이익률
March 2026 기준 영업이익률 TTM: 26.72%
AbbVie Inc.의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 26.72%입니다. 2024년 말 기준 영업이익률은 16.22%였습니다.
AbbVie Inc.의 영업이익률 기록 (2009 ~ 2026)
매년 말 영업이익률
연도 영업이익률 변화
2026 (TTM) 26.72% -22.97%
2025 34.69% 113.87%
2024 16.22% -30.95%
2023 23.49% -24.74%
2022 31.21% -2.13%
2021 31.89% 28.54%
2020 24.81% -36.43%
2019 39.03% 100.26%
2018 19.49% -42.39%
2017 33.83% -7.14%
2016 36.43% 10.49%
2015 32.97% 92.92%
2014 17.09% -43.30%
2013 30.14% -4.77%
2012 31.65% 52.53%
2011 20.75% -31.20%
2010 30.16% -13.08%
2009 34.70% 0.00%
유사 기업 또는 경쟁사의 영업이익률
회사 영업이익률 영업이익률 차이 국가
45.56% -98.29%
US
23.28% -99.13%
GB
27.17% -98.98%
US
31.24% -98.83%
CH
41.19% -98.46%
US
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.